G1 Therapeutics Inc (NASDAQ:GTHX) saw a large growth in short interest in the month of December. As of December 29th, there was short interest totalling 697,343 shares, a growth of 29.0% from the December 15th total of 540,660 shares. Approximately 4.3% of the shares of the stock are sold short. Based on an average daily volume of 124,734 shares, the days-to-cover ratio is presently 5.6 days.
G1 Therapeutics (NASDAQ:GTHX) opened at $23.04 on Friday. G1 Therapeutics has a fifty-two week low of $12.04 and a fifty-two week high of $28.67. The company has a market capitalization of $653.08 and a P/E ratio of -10.72.
In related news, insider Mark A. Velleca sold 7,500 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $20.01, for a total value of $150,075.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00. The disclosure for this sale can be found here. Insiders sold a total of 542,156 shares of company stock valued at $10,761,689 in the last ninety days.
Institutional investors have recently made changes to their positions in the business. RA Capital Management LLC purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $46,813,000. FMR LLC purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $34,093,000. Franklin Resources Inc. purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $10,651,000. Hillhouse Capital Management Ltd. purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $7,848,000. Finally, Laurion Capital Management LP purchased a new stake in shares of G1 Therapeutics in the second quarter valued at approximately $3,488,000. 43.25% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have commented on the company. Zacks Investment Research cut G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. BidaskClub raised G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, BTIG Research assumed coverage on G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $31.40.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.